Send us Fan Mail

Robin Carhart-Harris explains why his trial of psilocybin therapy vs. the SSRI escitalopram for depression missed one primary measure but favored psilocybin on almost everything else, and why SSRIs can blunt emotion.

TOPICS DISCUSSED:

• Consciousness Matters: Why the mind can drive biology, with placebo as the clearest example.
• Expectancy and Response: How beliefs and the quality of the experience shape outcomes.
• The Psilocybin vs. Escitalopram Trial: Not significantly different on the primary measure, but ahead on nearly every other outcome.
• The Blinding Problem: Why double-blind designs barely work here, and the case for open-label trials.
• Emotional Blunting: SSRIs dampened brain responses to emotional faces; psilocybin did not.
• Sexual Dysfunction: Worse on the SSRI, improved after psilocybin therapy.
• What's Next: Metabolic markers, fibromyalgia and a new trial in young adults with depression.

*Not medical advice.

Support the show

Support my work:

Good Chemistry: Personalized, science-based health consulting. Work with Dr. Nick Jikomes directly.
Affiliate Partners: Visit this link to see my affiliate partners and get discounts codes for products & services to support health.

For all the ways you can support my efforts.

Psilocybin vs. SSRIs for Depression, Emotional Blunting & How Psychedelics Work | Robin Carhart-Harris | Episode 310

Mind & Matter

Psilocybin vs. SSRIs for Depression, Emotional Blunting & How Psychedelics Work | Robin Carhart-Harris | Episode 310